Real‐world efficacy of ustekinumab and vedolizumab in pediatric and young adult patients with inflammatory bowel disease
Ustekinumab and vedolizumab are safe and effective in achieving clinical remission at 6 months and 1 year in PIBD. Comparative efficacy clinical trials are needed.
Authors
- Diane Hsu (ORCID: https://orcid.org/0000-0001-5475-886X)
- Alison Kotzen
- Alka Goyal (ORCID: https://orcid.org/0000-0002-9605-3734)
- Rachel Bensen
- Justin Lee (ORCID: https://orcid.org/0009-0008-3200-1020)
Institutions
- Stanford University (US)
Publication Details
- Journal
- Journal of Pediatric Gastroenterology and Nutrition
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1002/jpn3.70198
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00